United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Prism Readiness Cohort 10

Name: Biological Products, Excluding Disgnostic Substances Stocks in USA: Prism Readiness Cohort 10 comparison snapshot
Creator: Fliar BI Prism

A five-company biological products, excluding disgnostic substances cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 02 September 2026Not investment adviceRanked by Prism readiness

Readiness leaderCreative Medical Technologies · 37

Strongest available pathChampion Oncology · -49.6%

Widest latest marginChampion Oncology · 8.3%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1CELZ · Nasdaq

Creative Medical Technologies

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2011Phoenix, Arizona$7.4M market cap

View full Companies Radar profile

37Cautious

Snapshot price$1.13as of page date

Monthly-close return-98.5%five-year window

FY2025 revenue$0.00BCREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Net margin-99916.8%FY2025

P/E snapshot-1.3xone ratio, not a verdict

Prism attention7.0%share across these five

Filing track recordRevenue, USD billions

-93.2%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -48.9%

52-week position9% through range

$0.62$6.25

News mentions228

Community mentions0partial coverage

U.S.-scope patents1

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal44/100
Management stability90/100
Market position0/100
Capital-event signal39/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2SNTI · NASDAQ

Senti Biosciences

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2016San Francisco, California$10.6M market cap

View full Companies Radar profile

37Cautious

Snapshot price$0.34as of page date

Monthly-close return-99.7%five-year window

FY2025 revenue$0.00BSenti Biosciences, Inc.

Net margin-279263.6%FY2025

P/E snapshot-0.4xone ratio, not a verdict

Prism attention10.7%share across these five

Filing track recordRevenue, USD billions

-99.3%

FY2022–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -91.8%

52-week position0% through range

$0.33$2.88

News mentions351

Community mentions3partial coverage

U.S.-scope patents270

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal44/100
Management stability90/100
Market position7/100
Capital-event signal32/100
Innovation pulse3/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3ATYR · Nasdaq

aTyr Pharma

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2005San Diego, California$48.4M market cap

View full Companies Radar profile

37Cautious

Snapshot price$0.49as of page date

Monthly-close return-94.6%five-year window

FY2025 revenue$0.00BaTYR PHARMA INC

Net margin-39009.5%FY2025

P/E snapshot-1.1xone ratio, not a verdict

Prism attention19.4%share across these five

Filing track recordRevenue, USD billions

-98.2%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -63.3%

52-week position1% through range

$0.40$6.50

News mentions634

Community mentions30partial coverage

U.S.-scope patents534

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal33/100
Management stability90/100
Market position0/100
Capital-event signal51/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4CSBR · Nasdaq

Champion Oncology

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1985Hackensack, New Jersey$71.7M market cap

View full Companies Radar profile

36Cautious

Snapshot price$5.15as of page date

Monthly-close return-49.6%five-year window

FY2025 revenue$0.06BCHAMPIONS ONCOLOGY, INC.

Net margin8.3%FY2025

Prism attention5.9%share across these five

Filing track recordRevenue, USD billions

+38.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 8.5%

52-week position8% through range

$4.83$8.74

News mentions194

Community mentions0partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal47/100
Management stability90/100
Market position0/100
Capital-event signal30/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5RGNX · Nasdaq

Regenxbio

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2008Rockville, Maryland$633.7M market cap

View full Companies Radar profile

36Cautious

Snapshot price$9.60as of page date

Monthly-close return-77.1%five-year window

FY2025 revenue$0.17BREGENXBIO Inc.

Net margin-113.8%FY2025

P/E snapshot-3.2xone ratio, not a verdict

Prism attention57.0%share across these five

Filing track recordRevenue, USD billions

-63.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -22.4%

52-week position39% through range

$5.46$16.19

News mentions1.9K

Community mentions6partial coverage

U.S.-scope patents690

Prism InsightsWhat sits behind the readiness signal
Observed risk 7/100higher means more observed risk

Earnings signal21/100
Management stability90/100
Market position8/100
Capital-event signal74/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 4 M&A involvements, 0 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 2 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Champion Oncology

-49.6%

Regenxbio

-77.1%

aTyr Pharma

-94.6%

Creative Medical Technologies

-98.5%

Senti Biosciences

-99.7%

Latest revenue

USD billions, official filing scope shown on each company card.

Regenxbio

$0.17B

Champion Oncology

$0.06B

Creative Medical Technologies

$0.00B

Senti Biosciences

$0.00B

aTyr Pharma

$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Champion Oncology

8.3%

Regenxbio

-113.8%

aTyr Pharma

-39009.5%

Creative Medical Technologies

-99916.8%

Senti Biosciences

-279263.6%

Prism news attention

Normalized share across these five names; attention is not quality.

Regenxbio

57.0%

aTyr Pharma

19.4%

Senti Biosciences

10.7%

Creative Medical Technologies

7.0%

Champion Oncology

5.9%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Regenxbio leads the conversation

It holds 57.0% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $0.17B.

Price path

Champion Oncology leads the available price paths

Its monthly-close return is -49.6% for the five-year window. At the other end, Senti Biosciences is -99.7% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Champion Oncology has the widest latest margin

Its FY2025 net margin is 8.3%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Regenxbio shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -3.2x while its five-year window price return is -77.1%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · RGNX

Regenxbio

1,869available Prism news records

Prism top themes

Price action & investor response

Legal, arbitration & regulatory

Earnings & financial performance

Capital allocation & transactions

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-3.2%394 latest 12m vs 407 prior 12m

Machine-classified coverage tone

78.4% positive-11.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 177rare disease clinical trials 66rare disease treatment 66stock performance 45orphan drug pricing 36orphan drug incentives 27gene delivery systems 23patent litigation 20

Keyword tag occurrences in available Prism news records.

Coverage: 2012-08-01–2026-06-02 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

ATYR

aTyr Pharma

30 mentions

Stock and valuation

Products, pricing and logistics

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 30 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

CELZ

Creative Medical Technologies

through 2025-06-10

Earnings releases 2

2025-06-10
Earnings releases
Roth Capital also issued estimates for Creative Medical Technology’s Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.93) EPS, FY2025 earnings at ($3.00) EPS, FY2026 earnings at ($2.85) EPS, FY2027 earnings at $2.19 EPS, FY2028 earnings at $4.37 EPS and FY2029 earnings at $5.76 EPS.
2025-06-10
Earnings releases
Roth Capital analyst J. Aschoff now anticipates that the company will earn ($0.63) per share for the quarter, down from their previous forecast of ($0.40).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SNTI

Senti Biosciences

through 2025-12-18

Company announcements 6Leadership changes 5Business contracts 3Earnings releases 3M&A 2

2025-12-18
Company announcements
Senti Bio’s Board of Directors granted to one new employee stock options to purchase an aggregate of 13,680 shares of the Company’s common stock with a per share exercise price of $1.31 per share.
2025-05-12
Lawsuits
Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. ("Senti" or the "Company").
2025-03-14
Leadership changes
Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio,” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Feng Hsiung, an executive with extensive business, finance and investment experience, to the Senti Bio Board of Directors (the “Board”).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ATYR

aTyr Pharma

through 2025-09-08

Earnings releases 9Company announcements 7Leadership changes 4

2025-09-08
Company announcements
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted three employees nonstatutory stock options to purchase an aggregate of 62,400 shares of aTyr’s common stock, each with an exercise price of $5.71 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on September 3, 2025, the effective date of the grants.
2025-05-07
Earnings releases
Atyr Pharma Inc. (ATYR) on Wednesday reported a loss of $14.9 million in its first quarter.
2025-03-27
Leadership changes
aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”) today announced the appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CSBR

Champion Oncology

through 2025-03-12

Earnings releases 16Leadership changes 2

2025-03-12
Earnings releases
Year to Date Highlights: Total revenue increased 23% to $44.6 million
2025-01-09
Leadership changes
Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.
2025-03-11
Earnings releases
Total revenue increased 42% to $17.0 million

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RGNX

Regenxbio

through 2026-04-14

Earnings releases 13Leadership changes 13Lawsuits 2Listing / IPO 2Business contracts 1

2026-04-14
Lawsuits
According to the complaint filed in the U.S. District Court for the District of Maryland the plaintiff alleges on behalf of purchasers of REGENXBIO Inc. common shares between February 9, 2022 and January 27, 2026, that the defendants violated Federal Securities Laws.
2025-05-19
Business contracts
Regenxbio (RGNX) announced the closure of a non-dilutive, limited recourse royalty bond agreement of up to $250M with Healthcare Royalty.
2025-03-13
Earnings releases
For the year, the company reported a loss of $227.1 million, or $4.59 per share. Revenue was reported as $83.3 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence

2020 extracted base$194.20B–$477.15B

2033 extracted forecast$685.30B–$1.37T

Implied source CAGR8.5%

high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records

Latest 12m volume+9.8%10786 vs 9825 records

Positive classified tone41.7%+4.6 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies

4,078

substance abuse education

3,736

opioid addiction and treatment

3,643

overdose prevention techniques

3,482

controlled substance regulations

3,381

substance abuse overdose fatalities

3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576psychedelic mental health studies 1,328cannabis policy reform discussions 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 46–53. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 02 September 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Creative Medical Technologies leads the readiness ranking

Its Prism readiness score is 37/100, the highest in this five-company comparison.

Open Creative Medical Technologies in Companies Radar

Scale and margin leadership sit with Regenxbio and Champion Oncology

Regenxbio has the largest displayed latest revenue at $0.17B; Champion Oncology has the widest displayed latest margin at 8.3%.

Open Regenxbio in Companies Radar Open Champion Oncology in Companies Radar

Comparisons

Strongest versus weakest available price path

Champion Oncology is -49.6% for its five-year window; Senti Biosciences is -99.7% for its five-year window.

Open Champion Oncology in Companies Radar Open Senti Biosciences in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.17B for Regenxbio to $0.00B for aTyr Pharma. Entity and filing-period labels remain visible on the company cards.

Open Regenxbio in Companies Radar Open aTyr Pharma in Companies Radar

Anomalies

Regenxbio has the widest attention-readiness rank gap

It ranks #1 by measured news attention (57.0%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Regenxbio in Companies Radar

Champion Oncology shows a price-operating divergence to inspect

Its displayed filing-revenue change is +38.8% while its available monthly-close return is -49.6%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Champion Oncology in Companies Radar

Explanations

Attention measures coverage volume, not quality

Regenxbio's 57.0% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Regenxbio in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Creative Medical Technologies's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 37/100 score.

Open Creative Medical Technologies in Companies Radar

Stress-test the largest divergence before forming a view

Compare Champion Oncology's profile with Champion Oncology's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Champion Oncology in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.